Systematic Review of Medicine-Related Problems in Adult Patients with Atrial Fibrillation on Direct Oral Anticoagulants

New oral anticoagulant agents continue to emerge on the market and their safety requires assessment to provide evidence of their suitability for clinical use. There-fore, we searched standard databases to summarize the English language literature on medicine-related problems (MRPs) of direct oral an...

Full description

Bibliographic Details
Main Authors: Huda Alewairdhi, Nkiruka Umaru, Zoe Aslanpour
Format: Article
Language:English
Published: University of Huddersfield Press 2017-10-01
Series:British Journal of Pharmacy
Subjects:
Online Access:https://www.bjpharm.org.uk/article/id/33/
_version_ 1797821700786618368
author Huda Alewairdhi
Nkiruka Umaru
Zoe Aslanpour
author_facet Huda Alewairdhi
Nkiruka Umaru
Zoe Aslanpour
author_sort Huda Alewairdhi
collection DOAJ
description New oral anticoagulant agents continue to emerge on the market and their safety requires assessment to provide evidence of their suitability for clinical use. There-fore, we searched standard databases to summarize the English language literature on medicine-related problems (MRPs) of direct oral anticoagulants DOACs (dabigtran, rivaroxban, apixban, and edoxban) in the treatment of adults with atri-al fibrillation. Electronic databases including Medline, Embase, International Pharmaceutical Abstract (IPA), Scopus, CINAHL, the Web of Science and Cochrane were searched from 2008 through 2016 for original articles. Studies pub-lished in English reporting MRPs of DOACs in adult patients with AF were in-cluded. Seventeen studies were identified using standardized protocols, and two reviewers serially abstracted data from each article. Most articles were inconclusive on major safety end points including major bleeding. Data on major safety end points were combined with efficacy. Most studies inconsistently reported adverse drug reactions and not adverse events or medication error, and no definitions were consistent across studies. Some harmful drug effects were not assessed in studies and may have been overlooked. Little evidence is provided on MRPs of DOACs in patients with AF and, therefore, further studies are needed to establish the safety of DOACs in real-life clinical practice.
first_indexed 2024-03-13T09:57:40Z
format Article
id doaj.art-6bc5838189c746b7b118445620fc1a5e
institution Directory Open Access Journal
issn 2058-8356
language English
last_indexed 2024-03-13T09:57:40Z
publishDate 2017-10-01
publisher University of Huddersfield Press
record_format Article
series British Journal of Pharmacy
spelling doaj.art-6bc5838189c746b7b118445620fc1a5e2023-05-23T14:55:40ZengUniversity of Huddersfield PressBritish Journal of Pharmacy2058-83562017-10-012210.5920/bjpharm.2017.07Systematic Review of Medicine-Related Problems in Adult Patients with Atrial Fibrillation on Direct Oral AnticoagulantsHuda Alewairdhi Nkiruka UmaruZoe AslanpourNew oral anticoagulant agents continue to emerge on the market and their safety requires assessment to provide evidence of their suitability for clinical use. There-fore, we searched standard databases to summarize the English language literature on medicine-related problems (MRPs) of direct oral anticoagulants DOACs (dabigtran, rivaroxban, apixban, and edoxban) in the treatment of adults with atri-al fibrillation. Electronic databases including Medline, Embase, International Pharmaceutical Abstract (IPA), Scopus, CINAHL, the Web of Science and Cochrane were searched from 2008 through 2016 for original articles. Studies pub-lished in English reporting MRPs of DOACs in adult patients with AF were in-cluded. Seventeen studies were identified using standardized protocols, and two reviewers serially abstracted data from each article. Most articles were inconclusive on major safety end points including major bleeding. Data on major safety end points were combined with efficacy. Most studies inconsistently reported adverse drug reactions and not adverse events or medication error, and no definitions were consistent across studies. Some harmful drug effects were not assessed in studies and may have been overlooked. Little evidence is provided on MRPs of DOACs in patients with AF and, therefore, further studies are needed to establish the safety of DOACs in real-life clinical practice.https://www.bjpharm.org.uk/article/id/33/clinical practiceadult patientsatrial fibrillationoral anticoagulantsmedicine
spellingShingle Huda Alewairdhi
Nkiruka Umaru
Zoe Aslanpour
Systematic Review of Medicine-Related Problems in Adult Patients with Atrial Fibrillation on Direct Oral Anticoagulants
British Journal of Pharmacy
clinical practice
adult patients
atrial fibrillation
oral anticoagulants
medicine
title Systematic Review of Medicine-Related Problems in Adult Patients with Atrial Fibrillation on Direct Oral Anticoagulants
title_full Systematic Review of Medicine-Related Problems in Adult Patients with Atrial Fibrillation on Direct Oral Anticoagulants
title_fullStr Systematic Review of Medicine-Related Problems in Adult Patients with Atrial Fibrillation on Direct Oral Anticoagulants
title_full_unstemmed Systematic Review of Medicine-Related Problems in Adult Patients with Atrial Fibrillation on Direct Oral Anticoagulants
title_short Systematic Review of Medicine-Related Problems in Adult Patients with Atrial Fibrillation on Direct Oral Anticoagulants
title_sort systematic review of medicine related problems in adult patients with atrial fibrillation on direct oral anticoagulants
topic clinical practice
adult patients
atrial fibrillation
oral anticoagulants
medicine
url https://www.bjpharm.org.uk/article/id/33/
work_keys_str_mv AT hudaalewairdhi systematicreviewofmedicinerelatedproblemsinadultpatientswithatrialfibrillationondirectoralanticoagulants
AT nkirukaumaru systematicreviewofmedicinerelatedproblemsinadultpatientswithatrialfibrillationondirectoralanticoagulants
AT zoeaslanpour systematicreviewofmedicinerelatedproblemsinadultpatientswithatrialfibrillationondirectoralanticoagulants